Oncology News | pharmaphorum

News

FDA starts review of BMS's 'celmod' for multiple myeloma

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.

News

AstraZeneca raises guidance on stellar cancer drugs growth

AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

News

Grail multi-cancer test taps into Hims & Hers network

Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.

News

Eikon, Veradermics close IPOs, as Salspera joins queue

Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.

FDA starts review of BMS's 'celmod' for multiple myeloma

AstraZeneca raises guidance on stellar cancer drugs growth

Takeda signs $1.7bn AI alliance with Iambic

Flagship's AI-focused Generate Biomedicines files IPO

Grail multi-cancer test taps into Hims & Hers network

Eikon, Veradermics close IPOs, as Salspera joins queue

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks